Arctic Bioscience AS
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds in Norway, the United States, Europe, and Asia Pacific. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as int… Read more
Arctic Bioscience AS (ABS) - Total Assets
Latest total assets as of June 2025: Nkr290.35 Million NOK
Based on the latest financial reports, Arctic Bioscience AS (ABS) holds total assets worth Nkr290.35 Million NOK as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Arctic Bioscience AS - Total Assets Trend (2018–2024)
This chart illustrates how Arctic Bioscience AS’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Arctic Bioscience AS - Asset Composition Analysis
Current Asset Composition (December 2024)
Arctic Bioscience AS's total assets of Nkr290.35 Million consist of 20.7% current assets and 79.3% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 0.8% |
| Accounts Receivable | Nkr14.61 Million | 5.2% |
| Inventory | Nkr28.99 Million | 10.4% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr195.46 Million | 69.9% |
| Goodwill | Nkr1.93 Million | 0.7% |
Asset Composition Trend (2018–2024)
This chart illustrates how Arctic Bioscience AS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arctic Bioscience AS's current assets represent 20.7% of total assets in 2024, a decrease from 53.0% in 2018.
- Cash Position: Cash and equivalents constituted 0.8% of total assets in 2024, down from 0.8% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 69.0% of total assets, an increase from 39.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 69.9% of total assets.
Arctic Bioscience AS Competitors by Total Assets
Key competitors of Arctic Bioscience AS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Arctic Bioscience AS - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Arctic Bioscience AS generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Arctic Bioscience AS is currently not profitable relative to its asset base.
Arctic Bioscience AS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.83 | 2.06 | 2.32 |
| Quick Ratio | 0.34 | 1.21 | 1.16 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Nkr-11.63 Million | Nkr 38.40 Million | Nkr 29.95 Million |
Arctic Bioscience AS - Advanced Valuation Insights
This section examines the relationship between Arctic Bioscience AS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.48 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -6.8% |
| Total Assets | Nkr279.74 Million |
| Market Capitalization | $3.71 Million USD |
Valuation Analysis
Below Book Valuation: The market values Arctic Bioscience AS's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Arctic Bioscience AS's assets decreased by 6.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arctic Bioscience AS (2018–2024)
The table below shows the annual total assets of Arctic Bioscience AS from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr279.74 Million | -6.83% |
| 2023-12-31 | Nkr300.25 Million | -8.38% |
| 2022-12-31 | Nkr327.70 Million | -4.03% |
| 2021-12-31 | Nkr341.47 Million | +266.39% |
| 2020-12-31 | Nkr93.20 Million | +13.01% |
| 2019-12-31 | Nkr82.47 Million | +81.63% |
| 2018-12-31 | Nkr45.40 Million | -- |